Peptide LexiconAll compounds

Cartalax: Six Papers, All of Them in a Dish

Cartalax is a three-amino-acid peptide from the Russian bioregulator tradition. Its entire published record is six papers, every one of them cell culture — and the trial registry has never held a single entry for it.

PeptideCell-culture evidence onlyNo approved product

Caroline S · Published 2026-09-11

Length

3 amino acids

Sequence

Ala-Glu-Asp (alanine–glutamic acid–aspartic acid), abbreviated AED in the literature that studies it

Origin

One of the short synthetic peptides developed at the St Petersburg Institute of Bioregulation and Gerontology, the research tradition associated with Vladimir Khavinson.

Last reviewed

2026-09-11

What is it good for?

It is sold for cartilage, joints and connective tissue, and as a general anti-ageing bioregulator. The published work tests whether it changes how cells behave as they age in culture. Nothing in that work involves a joint, or a person.

Illustration: An empty cell culture petri dish on a white lab bench with a subtle green reflection.
Illustration

What it is

Cartalax is a peptide of three amino acids — alanine, glutamic acid and aspartic acid — written AED in the scientific literature that studies it. At three residues it is among the shortest compounds in this library.

It comes from a specific research tradition: the short-peptide bioregulators developed at the St Petersburg Institute of Bioregulation and Gerontology. That programme produced a family of very short synthetic peptides, each assigned to a tissue and given a trade name — AEDG as Epitalon for the pineal gland, KED, KE, EDL and others for their own targets. Cartalax is the one assigned to cartilage, and the name is doing the work that the evidence does not.

The whole published record

Six papers. That is the literature in its entirety, and reading all six takes less time than reading a single large trial report.

PubMed indexed 6 records for Cartalax on 2026-09-11, spanning 2011 to 2020:

  • 2011, Bulletin of Experimental Biology and Medicine — peptide regulation of thymocyte differentiation, proliferation and apoptosis in the ageing thymus.
  • 2014, Advances in Gerontology — tripeptides slowing the ageing process in renal cell culture. The abstract names AED and EDL and reports increased cell proliferation.
  • 2015, Bulletin of Experimental Biology and Medicine — cell renewal in kidney tissue cultures from young and old animals.
  • 2016, Bulletin of Experimental Biology and Medicine — skin fibroblast function during ageing in vitro.
  • 2019, International Journal of Immunopathology and Pharmacology — the effect of AED and related peptides on neuronal differentiation of precursors in human periodontal ligament stem cell cultures.
  • 2020, Molecular Biology Reports — gene expression in ageing human mesenchymal stem cell cultures.

Every one of these is a cell-culture study. Cells in a dish, in most cases deliberately aged in culture first, exposed to the peptide, then examined for proliferation or gene expression. Three of the six carry PubMed's human tag, and the tag means human cells — not human beings.

The registry has never held an entry for it

ClinicalTrials.gov returned zero registrations for Cartalax on 2026-09-11.

A keyword search does produce one hit, and it is worth naming because it is the kind of thing that ends up in a marketing page as "a registered clinical trial". The single result is NCT06852014, a Spanish study of an enteral nutrition formula called Peptamen 1.6 in malnourished patients with pancreatic disease, run by a research foundation in Málaga. It has nothing to do with this compound. It is a fuzzy text match on a similar-looking product name.

A registry hit is not a registry record until somebody opens it. This library has had to make that correction before, in the opposite direction — two live entries once cited registrations that turned out to belong to a sponsor whose filings did not withstand checking.

What is missing

The thing worth saying plainly about this compound is not that its evidence is weak. It is that the evidence does not address the claim at all.

Cartalax is sold for cartilage, joints and connective tissue. Not one of the six published papers measures cartilage, joint function, stiffness or pain — not in a person, not in an animal, not even in cartilage cells specifically. The studies look at thymocytes, kidney cells, skin fibroblasts, stem cells. The joint claim rests entirely on the naming convention of the programme that produced it.

That is a different situation from, say, GHK-Cu, where one small randomized trial exists and was negative on its objective endpoints, or the MOTS-c file, where a large literature measures the wrong thing. Here there is no measurement of the claimed outcome at any level of biological organisation.

Where it stands

There is no approved product anywhere. DailyMed and Drugs@FDA returned nothing on 2026-09-11. It is sold as a research powder and, within the bioregulator product range, as an oral capsule — a route for which the published record offers nothing at all, since none of the six studies involved a digestive tract.

Search interest in it has been climbing steeply, and its link competition is the lowest this network has measured for any compound. Neither of those facts is evidence about the compound. They are facts about the market.

Within the same research tradition, the Epitalon file is substantially larger, and Thymalin — from the same St Petersburg institute — has close to three hundred papers and a clinical history in Russia, which makes the contrast with this entry's six instructive. For the broader picture of what is and is not established in this category, see peptides for longevity and peptides for joints and tendons.

What the research shows

Changes gene expression and proliferation in aged cell cultures

This is what all six published papers examine, and several report effects

Has been given to a person in a published study

No published human administration found

Has a registered clinical trial anywhere

Zero registrations on ClinicalTrials.gov

Does anything for cartilage or joints in a living body

No study in the published record measures cartilage, joint function or pain in any animal or person

Bars show how much of the evidence is in humans, not how well anything works.

Where it stands

United States

No approved medicine and no product record. Searches of DailyMed and Drugs@FDA on 2026-09-11 returned nothing.

Published record

PubMed indexed 6 records for Cartalax on 2026-09-11, spanning 2011 to 2020. Three carry a human tag, and all three are studies of human cells in culture. Most appear in Russian gerontology and experimental-biology journals.

Trial registry

Zero registrations on ClinicalTrials.gov (2026-09-11). A keyword search does return one result — a nutrition study of an enteral formula called Peptamen 1.6 — which has nothing to do with this compound and is a text match, not a record of it.

How it is sold

As a lyophilised research powder, and in oral capsule form within the bioregulator product range.

Frequently asked questions

What is Cartalax?

A synthetic peptide of three amino acids — alanine, glutamic acid and aspartic acid, written AED in the scientific literature. It comes from the short-peptide bioregulator programme associated with the St Petersburg Institute of Bioregulation and Gerontology, which produced a family of two-, three- and four-residue peptides each assigned to a tissue. Cartalax is the one assigned to cartilage.

What does the research actually show?

That in cell culture, it changes things. The six published papers report effects on proliferation and gene expression in aged cells — kidney cultures, skin fibroblasts, stem cells. Those are real experiments with real results. What they are not is evidence about a joint, a body or a person, and no paper in the record claims otherwise.

Has anyone taken it in a study?

Not in any study that has been published or registered. PubMed held six records on 2026-09-11 and all six are cell culture. ClinicalTrials.gov held zero registrations. There is no published safety data in humans and no tested dose.

Why is it sold for joints and cartilage?

Because of how the bioregulator programme was organised rather than because of a measured outcome. Each peptide in that family was assigned a target tissue and named accordingly — this one for cartilage. The sales claim follows the naming convention. No study in its published record measures cartilage, joint function, stiffness or pain in any living animal, let alone a person.

Its search interest is rising sharply. Does that mean anything?

It means the marketing is working, and nothing else. Search demand and evidence are independent quantities, and this library has repeatedly found them moving in opposite directions. A compound with six cell-culture papers has the evidence base of a compound with six cell-culture papers however many people are looking it up.

How does it compare with the other bioregulator peptides?

It is one of the thinner files in that family. Epitalon, the pineal peptide from the same programme, has a considerably larger literature including human work, and Thymalin — the thymus preparation from the same institute — has almost three hundred papers and a long clinical tradition in Russia. Cartalax has six papers in a dish. Within its own tradition it is not a well-studied compound.

What would change the picture?

A single study in a living organism. Not a trial in people — an animal study with a measured outcome in a joint would be a large step up from where this record currently sits. The gap between cell culture and a body is the gap that most promising compounds fail to cross, and this one has not attempted it in public.